Get the Stockscreener App
2.60
3.59%
0.09
After Hours:
2.59
-0.01
-0.38%
Organogenesis Holdings Inc stock is traded at $2.60, with a volume of 963.85K.
It is up +3.59% in the last 24 hours and down -1.52% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$2.51
Open:
$2.5
24h Volume:
963.85K
Relative Volume:
0.90
Market Cap:
$334.47M
Revenue:
$564.17M
Net Income/Loss:
$37.03M
P/E Ratio:
23.74
EPS:
0.1095
Net Cash Flow:
$-24.46M
1W Performance:
+8.79%
1M Performance:
-1.52%
6M Performance:
-36.12%
1Y Performance:
-39.81%
1-Day Range:
$2.49
$2.625
1-Week Range:
$2.225
$2.625
52-Week Range:
$2.21
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.60 | 322.89M | 564.17M | 37.03M | -24.46M | 0.1095 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
3 Penny Stocks With Market Caps Under $400M To Consider - simplywall.st
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens - FinancialContent
Organogenesis shares jump 20% following positive clinical trial results - MSN
What's going on with Organogenesis stock on Wednesday? - MSN
Options Flow: Will Organogenesis Holdings Inc benefit from rate cuts2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
720p-h264Dailyhunt - Dailyhunt
What's Going On With Organogenesis Stock On Wednesday? - Sahm
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight (NASDAQ:ORGO) - Seeking Alpha
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
Organogenesis stock rockets after diabetic foot ulcer trial posts statistically significant win - MSN
PuraPly AM Triumphs in Wound Healing Trial, Paves Way for New Successes - StocksToTrade
Organogenesis’ Clinical Trials Propel Stock Amid FDA Progress - timothysykes.com
Organogenesis stock surges 20% on trial results By Investing.com - Investing.com Australia
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win - Benzinga
Organogenesis stock surges 20% on trial results - Investing.com
Organogenesis stock up as PuraPlyAM succeeds (ORGO:NASDAQ) - Seeking Alpha
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 - Bitget
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com Canada
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPlyAM - Bitget
ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment - Stocktwits
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM - The Manila Times
In 170-patient diabetic foot ulcer study, Organogenesis clears key goal - Stock Titan
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain - Bitget
Organogenesis Cleared to Begin Rolling BLA for ReNu Knee Osteoarthritis Therapy - marketscreener.com
Regenerative medicine giant Organogenesis Holdings Inc (ORGO) recently announced the successful completion of a key meeting with the U.S. Food and Drug Administration (FDA). - Bitget
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain - The Manila Times
Knee pain treatment for 31 million Americans moves toward FDA filing - stocktitan.net
New York real estate firm acquires Organogenesis property for $68M - Providence Business News
ORGO SEC FilingsOrganogenesis Hldgs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Movement Recap: Whats the fair value of Organogenesis Holdings Inc stockQuarterly Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Published on: 2026-03-31 10:52:09 - baoquankhu1.vn
IPO Launch: Is Organogenesis Holdings Inc impacted by rising rates2026 Historical Comparison & High Conviction Buy Zone Alerts - baoquankhu1.vn
Dividend Watch: Whats the fair value of Organogenesis Holdings Inc stock2026 Technicals & Weekly High Conviction Ideas - baoquankhu1.vn
Organogenesis Facing Hard Times As It Adjusts To CMS Rule Changes (NASDAQ:ORGO) - Seeking Alpha
Asia Pacific Wound Care Biologics Market Projected to Witness - openPR.com
Organogenesis (NASDAQ:ORGO) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates Buy Rating and $8 Price Target for ORGO | ORGO S - GuruFocus
Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO - MarketBeat
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organogenesis Holdings Inc Stock (ORGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):